Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Regulatory News (COG)

Share Price Information for Cambridge Cog (COG)

Share Price is delayed by 15 minutes
Get Live Data
34.00    0.00 (0.00%)
Bid:
33.00
Ask:
35.00
Spread: 2.00 (6.061%)
Market Cap: £15.83m
COG Live PriceLast checked at - London Stock Exchange

Intraday Cambridge Cog Share Chart

Delayed Preliminary Results

23 Mar 2020 16:00

RNS Number : 2589H
Cambridge Cognition Holdings PLC
23 March 2020
 

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

 

Delayed Preliminary Results

 

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, announces a delay in the publication of its preliminary results following guidance from the Financial Conduct Authority ("FCA").

 

Cambridge Cognition was ready to release its preliminary financial results for the year ended 31 December 2019 on 24 March 2020. However, the FCA has strongly requested that all listed companies observe a moratorium on the publication of preliminary financial statements for at least two weeks from today's date. Whilst Cambridge Cognition as an AIM quoted company is not formally covered by this request, the Company will be observing this moratorium following advice from its auditors, Grant Thornton. Current guidance is that the Company may need to defer issuing its results for the year ended 31 December 2019 until such time as they are audited.

 

Further information on a revised timetable for publication of the Company's financial statements will be provided in due course.

 

The Company announced a trading update in respect of the year ended 31 December 2019 on 19 February 2020 and the Company anticipates no material differences to the information provided in that announcement.

 

 

Enquiries:

 

Cambridge Cognition Holdings plc

Tel: 01223 810 700

Matthew Stork, Chief Executive Officer

press@camcog.com

Nick Walters, Chief Financial Officer

finnCap Ltd (Nomad and Joint Broker)

Tel: 020 7220 0500

Geoff Nash/ Simon Hicks

(Corporate Finance)

Alice Lane/ Manasa Patil

(Corporate Broking)

Dowgate Capital Limited (Joint Broker)

Tel: 020 3903 7715

David Poutney/ James Serjeant

IFC Advisory Ltd (Financial PR and IR)

Tel: 020 3934 6630

Tim Metcalfe/ Graham Herring/ Zach Cohen

 

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NORBUGDXSSDDGGX
Date   Source Headline
31st May 20237:00 amRNSCapital Markets Day
3rd May 20237:00 amRNSResults for the year ended 31 December 2022
26th Apr 20237:00 amRNSInvestor Webinar and Analyst Briefing
20th Apr 20237:00 amRNSNotice of Results
12th Apr 20237:00 amRNS£2.1 million contracts for rare disease trials
21st Mar 20237:00 amRNSBlock Admission Application & Exercise of Options
6th Feb 20237:00 amRNSDirector/PDMR Share Purchases
31st Jan 20237:00 amRNSTrading Update
30th Jan 20231:14 pmRNSHolding(s) in Company
18th Jan 20231:14 pmRNSHolding(s) in Company
18th Jan 202312:22 pmRNSHolding(s) in Company
17th Jan 20235:54 pmRNSHolding(s) in Company
17th Jan 20234:06 pmRNSHolding(s) in Company
13th Jan 20235:09 pmRNSHolding(s) in Company
11th Jan 20237:00 amRNSAcquisition of Winterlight Labs Inc
24th Nov 20227:00 amRNSStrategic Partnership for Chinese Market Expansion
19th Oct 20227:00 amRNS£1.1 million eCOA contract win
12th Oct 20227:00 amRNSAcquisition of eClinicalHealth Limited
20th Sep 20227:00 amRNSInterim Results
1st Sep 20227:00 amRNS£2.2m neurodegenerative disease trial contract
17th Aug 20227:00 amRNSAlzheimer’s Disease Validation for NeuroVocalix
3rd Aug 20222:55 pmRNSDirectorate Change
28th Jul 20227:00 amRNSPTSD trials with top 10 pharma company & US DoD
26th Jul 20227:00 amRNSGrant of Options
22nd Jul 202211:05 amRNSSecond Price Monitoring Extn
22nd Jul 202211:00 amRNSPrice Monitoring Extension
22nd Jul 20227:00 amRNSDirector/PDMR Share Purchases
21st Jul 20227:00 amRNSTrading Update and Notice of Results
14th Jul 202211:06 amRNSSecond Price Monitoring Extn
14th Jul 202211:00 amRNSPrice Monitoring Extension
30th Jun 20225:43 pmRNSHolding(s) in Company
8th Jun 20223:14 pmRNSResult of AGM
16th May 20224:35 pmRNSPosting of Annual Report & Notice of AGM
12th Apr 20227:00 amRNSResults for the year ended 31 December 2021
6th Apr 20227:00 amRNSSenior Management Appointments
31st Mar 20227:00 amRNSNotice of Results
29th Mar 20222:06 pmRNSSecond Price Monitoring Extn
29th Mar 20222:00 pmRNSPrice Monitoring Extension
28th Mar 20224:41 pmRNSSecond Price Monitoring Extn
28th Mar 20224:35 pmRNSPrice Monitoring Extension
28th Mar 20227:00 amRNS£1 million contract for pivotal autoimmune trial
24th Mar 20227:00 amRNSAppointment of Nominated Adviser and Joint Broker
4th Feb 202212:06 pmRNSHolding(s) in Company
2nd Feb 20227:00 amRNS£2.1 million contract
27th Jan 20227:00 amRNSTrading Update
10th Jan 20227:00 amRNSNew Major Pharma Client for Schizophrenia Trials
16th Dec 20217:00 amRNSElectronic Clinical Outcomes Assessment Contract
9th Dec 20217:00 amRNS£1.0m Schizophrenia clinical trial contract
22nd Nov 202111:50 amRNSHolding(s) in Company
16th Nov 20217:00 amRNSGrant of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.